| Abstrakt: |
Researchers at Beth Israel Deaconess Medical Center in Boston, Massachusetts, have developed a mass spectrometric-based workflow to identify and quantify a P-selectin antagonist, GSnP-6, with a linear 10 kDa PEG attached. This modification improved the pharmacological properties of the glycopeptide, extending its half-life while preserving its inhibitory capacity. The study suggests that PEG conjugation of a P-selectin glycopeptide antagonist could be a promising therapeutic strategy for diseases associated with inflammatory processes. For more information, the research article can be found in RSC Advances, and the lead researcher is Elliot L. Chaikof from Harvard Medical School. [Extracted from the article] |
